In this video interview, Dr. Nassir Marrouche, Executive Director of the Comprehensive Arrhythmia Research and Management (CARMA) Center at the University of Utah Health System, discusses the findings he recently presented at the Heart Rhythm Society annual meeting in Denver. He discussed the intriguing way they are using MRI (magnetic resonance imaging), to personalize atrial fibrillation (AF) treatment by determining the degree of atrial fibrosis in the atrium to determine whether catheter ablation is likely to work. Since the extent of atrial fibrosis also correlates with stroke risk, this “staging” approach also can dictate whether anticoagulation is needed following the procedure.
The effectiveness of this Utah AF staging system will be tested through a multicenter clinical trial involving Cleveland Clinic, Mayo Clinic, the University of Pennsylvania, Loyola, CHU Bordeaux, and a number of other centers around the world.
Watch the video: